Calhoun Vision said yesterday that it’s replacing CEO Verne Sharma with Rick Heinick, a former Bausch & Lomb executive who helped lead the firm until its acquisition by Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) in 2013.
Heinick’s résumé includes stints as executive vice president & chief human resources & transformation officer at Bausch & Lomb, executive vice president of construction firm Aecom and senior partner at Schaffer Consulting. He was also the founder & CEO of Personal Performance Software.
"Rick’s experience and proven leadership ability is crucial to Calhoun as we focus on the vital task of obtaining FDA approval for the light-adjustable lens. Rick has a demonstrated track record of forming and leading high performance teams that get results," Calhoun Vision chairman Andy Corley said in prepared remarks.
The LAL device uses a unique blend of light-sensitive polymers to create a customized lens to correct astigmatism, myopia and hyperopia, Sharma told MassDevice.com last year.
"Calhoun’s novel LAL technology allows ophthalmologists to tailor the power of an intraocular lens after implantation in the eye following cataract surgery, providing unparalleled customization for patients," Heinick said in a statement. "I look forward to working with the Calhoun team to advance this groundbreaking technology to address unmet needs in ophthalmology, as well as positioning the company for continued growth and success."
Carpou is new CEO at OCTANe
OCTANe, the Orange County Technology Action Network, said it named Bill Carpou to be its new CEO. Carpou succeeds Matthew Jenusaitis, who will retain a seat on the OCTANe board.
Insulet taps Dune Medical, Hologic vets
Insulet (NSDQ:PODD) added medtech veterans to its executive roster, naming former Dune Medical Devices CEO Daniel Levangie to the newly-created role of drug delivery president and ex-Hologic (NSDQ:HOLX) and Cytyc exec Shacey Petrovic as chief commercial officer. The company said it named Dr. John Fallon to replace Levangie as lead director.
Spectranetics CFO Childs to step down
Spectranetics (NSDQ:SPNC) CFO Guy Childs is stepping down from his finance chief role but will stay on as vice president of treasury, investor relations & financial planning.
Hill-Rom names former Ev3, Covidien exec Seng to board
Stacy Enxing Seng was elected to the board of directors at Hill-Rom Holdings (NYSE:HRC). Seng led Ev3’s peripheral vascular business until its $2.3 billion acquisition by Covidien in 2010. Medtronic paid $50 billion for Covidien in January